Dendrimers are described as “tree-like, non-cytotoxic polymeric drug delivery vehicles” and were used to deliver steroid drugs to activated microglial cells, the immune cells in charge of removing dead and dying material in the eye. The dendrimers slowly released steroids, and provided neuroprotection for at least a month in clinical trials using rats. The steroids only targeted the activated microglia that cause damage associated with neuroinflammation, a leading cause of both macular degeneration and retinitis pigmentosa.
Related Articles on Ophthalmology:
Photorefractive Keratectomy Gaining Popularity Over LASIK
Premium IOLs a Challenge to Adopt Into Cataract Practice
ASC Specialty to Watch: Ophthalmology in 2012
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.